Stay updated with breaking news from Mark Douglas Smith. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Robert W. Baird assumed coverage on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ – Free Report) in a research report released on Wednesday morning, MarketBeat Ratings reports. The firm issued an outperform rating and a $160.00 price objective on the specialty pharmaceutical company’s stock. Several other analysts also recently issued reports on the company. Truist Financial restated […]
Compass Wealth Management LLC trimmed its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report) by 5.7% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 5,500 shares of the specialty pharmaceutical company’s stock after selling 335 shares during the quarter. Compass Wealth Management LLC’s holdings in Jazz Pharmaceuticals were worth $712,000 as […]
Truist Financial reiterated their buy rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ – Free Report) in a research note issued to investors on Monday morning, Benzinga reports. They currently have a $200.00 target price on the specialty pharmaceutical company’s stock. A number of other equities research analysts have also recently issued reports on JAZZ. HC […]
Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the nine brokerages that are covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month […]
Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Get Free Report) have been given an average rating of “Moderate Buy” by the nine research firms that are currently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average […]